Home Healthcare Pharmaceuticals Spinal Muscular Atrophy Treatment Market

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By SMA Type (Severe (type I, severe SMA or Werdnig-Hoffmann disease), Intermediate (type II or chronic SMA), Mild (type III, juvenile SMA or Kugelberg-Welander disease), Type IV (adult SMA)), By Treatment (Gene Therapy, Drugs, Medication, Physical Therapy, Surgery, Others), By Route of Administration (Oral, Intrathecal, Paranteral), By Drug (Nusinersen, Onasemnogene, Abeparvovec, Others), By Administration (Intrathecal, Intraspinal, Subcutaneous, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR604DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Spinal Muscular Atrophy Treatment Market, By SMA Type 2022-2034 (USD MILLION/ Units)
    1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
    2. Intermediate (type II or chronic SMA)
    3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
    4. Type IV (adult SMA)
  2. Spinal Muscular Atrophy Treatment Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Gene Therapy
    2. Drugs
    3. Medication
    4. Physical Therapy
    5. Surgery
    6. Others
  3. Spinal Muscular Atrophy Treatment Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Intrathecal
    3. Paranteral
  4. Spinal Muscular Atrophy Treatment Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Nusinersen
    2. Onasemnogene
    3. Abeparvovec
    4. Others
  5. Spinal Muscular Atrophy Treatment Market, By Administration 2022-2034 (USD MILLION/ Units)
    1. Intrathecal
    2. Intraspinal
    3. Subcutaneous
    4. Others
  6. Spinal Muscular Atrophy Treatment Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  7. Spinal Muscular Atrophy Treatment Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Others
  8. Regional Spinal Muscular Atrophy Treatment Market
    1. North America
      1. North America Spinal Muscular Atrophy Treatment Market By SMA Type 2022-2034 (USD MILLION/ Units)
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
      2. North America Spinal Muscular Atrophy Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Drugs
        3. Medication
        4. Physical Therapy
        5. Surgery
        6. Others
      3. North America Spinal Muscular Atrophy Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intrathecal
        3. Paranteral
      4. North America Spinal Muscular Atrophy Treatment Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Nusinersen
        2. Onasemnogene
        3. Abeparvovec
        4. Others
      5. North America Spinal Muscular Atrophy Treatment Market By Administration 2022-2034 (USD MILLION/ Units)
        1. Intrathecal
        2. Intraspinal
        3. Subcutaneous
        4. Others
      6. North America Spinal Muscular Atrophy Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      7. North America Spinal Muscular Atrophy Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      8. U.S.
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      9. Canada
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
    2. Europe
      1. Europe Spinal Muscular Atrophy Treatment Market By SMA Type 2022-2034 (USD MILLION/ Units)
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
      2. Europe Spinal Muscular Atrophy Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Drugs
        3. Medication
        4. Physical Therapy
        5. Surgery
        6. Others
      3. Europe Spinal Muscular Atrophy Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intrathecal
        3. Paranteral
      4. Europe Spinal Muscular Atrophy Treatment Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Nusinersen
        2. Onasemnogene
        3. Abeparvovec
        4. Others
      5. Europe Spinal Muscular Atrophy Treatment Market By Administration 2022-2034 (USD MILLION/ Units)
        1. Intrathecal
        2. Intraspinal
        3. Subcutaneous
        4. Others
      6. Europe Spinal Muscular Atrophy Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      7. Europe Spinal Muscular Atrophy Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      8. U.K.
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      9. Germany
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      10. France
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      11. Spain
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      12. Italy
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      13. Russia
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      14. Nordic
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      15. Benelux
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      16. Rest of Europe
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
    3. APAC
      1. APAC Spinal Muscular Atrophy Treatment Market By SMA Type 2022-2034 (USD MILLION/ Units)
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
      2. APAC Spinal Muscular Atrophy Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Drugs
        3. Medication
        4. Physical Therapy
        5. Surgery
        6. Others
      3. APAC Spinal Muscular Atrophy Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intrathecal
        3. Paranteral
      4. APAC Spinal Muscular Atrophy Treatment Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Nusinersen
        2. Onasemnogene
        3. Abeparvovec
        4. Others
      5. APAC Spinal Muscular Atrophy Treatment Market By Administration 2022-2034 (USD MILLION/ Units)
        1. Intrathecal
        2. Intraspinal
        3. Subcutaneous
        4. Others
      6. APAC Spinal Muscular Atrophy Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      7. APAC Spinal Muscular Atrophy Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      8. China
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      9. Korea
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      10. Japan
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      11. India
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      12. Australia
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      13. Taiwan
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      14. South East Asia
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      15. Rest of Asia-Pacific
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
    4. Middle East and Africa
      1. Middle East and Africa Spinal Muscular Atrophy Treatment Market By SMA Type 2022-2034 (USD MILLION/ Units)
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
      2. Middle East and Africa Spinal Muscular Atrophy Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Drugs
        3. Medication
        4. Physical Therapy
        5. Surgery
        6. Others
      3. Middle East and Africa Spinal Muscular Atrophy Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intrathecal
        3. Paranteral
      4. Middle East and Africa Spinal Muscular Atrophy Treatment Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Nusinersen
        2. Onasemnogene
        3. Abeparvovec
        4. Others
      5. Middle East and Africa Spinal Muscular Atrophy Treatment Market By Administration 2022-2034 (USD MILLION/ Units)
        1. Intrathecal
        2. Intraspinal
        3. Subcutaneous
        4. Others
      6. Middle East and Africa Spinal Muscular Atrophy Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      7. Middle East and Africa Spinal Muscular Atrophy Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      8. UAE
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      9. Turkey
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      10. Saudi Arabia
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      11. South Africa
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      12. Egypt
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      13. Nigeria
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      14. Rest of MEA
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
    5. LATAM
      1. LATAM Spinal Muscular Atrophy Treatment Market By SMA Type 2022-2034 (USD MILLION/ Units)
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
      2. LATAM Spinal Muscular Atrophy Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Drugs
        3. Medication
        4. Physical Therapy
        5. Surgery
        6. Others
      3. LATAM Spinal Muscular Atrophy Treatment Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intrathecal
        3. Paranteral
      4. LATAM Spinal Muscular Atrophy Treatment Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Nusinersen
        2. Onasemnogene
        3. Abeparvovec
        4. Others
      5. LATAM Spinal Muscular Atrophy Treatment Market By Administration 2022-2034 (USD MILLION/ Units)
        1. Intrathecal
        2. Intraspinal
        3. Subcutaneous
        4. Others
      6. LATAM Spinal Muscular Atrophy Treatment Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
      7. LATAM Spinal Muscular Atrophy Treatment Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
      8. Brazil
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      9. Mexico
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      10. Argentina
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      11. Chile
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      12. Colombia
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
      13. Rest of LATAM
        1. Severe (type I, severe SMA or Werdnig-Hoffmann disease)
        2. Intermediate (type II or chronic SMA)
        3. Mild (type III, juvenile SMA or Kugelberg-Welander disease)
        4. Type IV (adult SMA)
        5. Gene Therapy
        6. Drugs
        7. Medication
        8. Physical Therapy
        9. Surgery
        10. Others
        11. Oral
        12. Intrathecal
        13. Paranteral
        14. Nusinersen
        15. Onasemnogene
        16. Abeparvovec
        17. Others
        18. Intrathecal
        19. Intraspinal
        20. Subcutaneous
        21. Others
        22. Hospital Pharmacy
        23. Retail Pharmacy
        24. Online Pharmacy
        25. Hospitals
        26. Homecare
        27. Specialty Clinics
        28. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.